Skip to main content

Table 1 Demographics and clinical characteristics of 605 eligible patients before PSM

From: Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

Characteristic Variable Before PSM
No-PBT PBT P value
(n = 512) (n = 93)
Age Y ± SD 57.42 ± 10.815 56.54 ± 11.801 0.176a
Gender female/ male 190/322 48/45 0.008c
Preoperative Hb g/L ± SD 132.53 ± 16.22 118.63 ± 17.68 0.329a
Platelet 1 × 109/L ± SD 179.25 ± 64.02 201.30 ± 97.35 0.038a
Total bilirubin available data 510(99.61%) 92 (98.92%)  
umol /L ± SD 24.98 ± 55.35 86.79 ± 134.47 <0.001b
AST available data 502(98.05%) 90 (96.77%)  
U/L ± SD 44.56 ± 87.09 56.21 ± 57.45 <0.001b
ALT available data 509 (99.41%) 92 (98.92%)  
U/L ± SD 50.40 ± 95.22 57.90 ± 67.28 0.002b
AFP available data 497 (97.07%) 91 (97.85%)  
ng/mL ± SD 95.28 ± 953.72 93.02 ± 585.95 0.982b
CEA available data 489 (95.51%) 87 (93.55%)  
ng/mL ± SD 22.42 ± 154.07 61.84 ± 330.14 0.060b
CA19–9 available data 486 (94.92%) 86 (92.47%)  
U/mL ± SD 1152.16 ± 3116.14 2698.09 ± 4923.75 <0.001b
PT available data 506 (98.83%) 91 (97.85%)  
s ± SD 11.20 ± 9.23 11.87 ± 3.11 0.093b
INR available data 502 (98.05%) 89 (95.70%)  
  Value ±SD 0.98 ± 0.11 0.98 ± 0.14 0.910b
HBsAg available data 506 (98.83%) 93 (100.00%)  
(−)/(+) 302/204 71/22 0.002c
Anti-HCV available data 502 (98.05%) 93 (100.00%)  
(−)/(+) 493/9 91/2 0.814c
Tumor number available data 511 (99.80%) 92 (98.92%)  
1/>1 426/85 81/11 0.259c
TMD available data 509 (99.41%) 93 (100.00%)  
cm 6.48 ± 3.16 6.92 ± 3.44 0.284b
TNM stage available data 489 (95.51%) 74 (79.57%)  
I/II/III/IVa 294/80/17/98 47/15/0/12 0.433c
Cirrhotic nodule available data 512 (100.00%) 91 (97.85%)  
no/ yes 344/168 70/21 0.065c
DD available data 412 (80.47%) 76 (81.72%)  
I/II-III/IV 2/408/2 (0.49%) 0/76/0 (0.00%) 1.000c
IBL available data 503 (98.24%) 93 (100.00%)  
<1 L/≥1 L 499/4 (99.20%) 61/32 (65.59%) <0.001c
Preventive TACE no/yes 474/38 (92.58%) 86/7 (92.47%) 0.972c
Propensity Score available data 501 (84.49%) 92 (15.51%)  
   0.096 ± 0.104 0.479 ± 0.372 <0.001b
  1. at test
  2. bK-Independent-Samples Test (Kruskal Wallis H(K) test)
  3. cTwo-Independent-Samples Test (Mann-Whitney U test)
  4. Values are presented as n (%) or mean ± standard deviation(SD)
  5. Hb: hemoglobin; AST: aspartate aminotransferase; ALT: alanine transaminase; AFP: alpha fetoprotein; CEA: carcinoembryonic antigen; CA19–9: carbohydrate antigen 19–9; PT: prothrombin time; INR: international normalized ratio; HBsAg: hepatitis B surface antigen; Anti-HCV: anti-hepatitis C virus; TMD: tumor maximum dimension; TNM: tumor node metastasis; IBL: intraoperative blood loss; DD: The degree of differentiation;
  6. TACE: transcatheter arterial chemoembolization. PSM: propensity score matching; No-PBT: no-perioperative transfusion; PBT: perioperative transfusion